EUVIMEDDécouvrir EUVIMED
Open access · CC BY-NC-ND 4.0

Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury

Miguel Fontecha-Barriuso, Natalia Villar-Gomez, Juan Guerrero-Mauvecin, Julio M Martinez-Moreno iD, Susana Carrasco, Diego Martin-Sanchez, María Rodríguez-Laguna, Manuel J Gómez, María D Sanchez-Niño, Marta Ruiz-Ortega, Alberto Ortiz, Ana B Sanz iD

The Journal of Pathology · 2024-12 · 264 (4) · 396-410

DOI: 10.1002/path.6355 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2024-10-29. Written by Miguel Fontecha-Barriuso and 11 co-authors. Institution: Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, Madrid…. Major MEDLINE topics: Acute Kidney Injury, Core Binding Factor Alpha 2 Subunit, Lipopolysaccharides. Cited 11 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: COST (European Cooperation in Science and Technology), Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040, European Cooperation in Science and Technology.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Treatment for acute kidney injury (AKI) is suboptimal. A better understanding of the pathogenesis of AKI may lead to new therapeutic approaches. Kidney transcriptomics of folic acid‐induced AKI (FA‐AKI) in mice identified Runx1 as the most upregulated RUNX family gene. We then examined the expression of RUNX1 in FA‐AKI, in bacterial lipopolysaccharide (LPS)‐induced cytokine storm‐AKI (CS‐AKI), and in human AKI. In cultured mouse tubule cells, we explored the expression and role of RUNX1 in response to the cytokine TWEAK or LPS. A chemical inhibitor of RUNX1 (Ro5‐3335) was used in animal models of AKI to test its potential as a therapeutic target. RUNX1 overexpression in FA‐AKI was validated at the mRNA and protein levels and localized mainly to tubule cell nuclei. CS‐AKI also upregulated kidney RUNX1. Increased tubule and interstitial RUNX1 expression were also observed in human AKI. In cultured mouse tubule cells, the pro‐inflammatory cytokine TWEAK and LPS increased RUNX1 and IL‐6 expression. Mechanistically, RUNX1 bound to the Il6 gene promoter and RUNX1 targeting with the chemical inhibitor Ro5‐3335, or a specific small interfering RNA (siRNA), prevented the TWEAK‐ and LPS‐induced upregulation of IL6 through a RUNX1/NFκB1 p50 pathway. In vivo , preventive Ro5‐3335 improved kidney function and reduced inflammation in FA‐AKI and CS‐AKI. However, Ro5‐3335 administration after the insult only improved kidney function in CS‐AKI. Kidney transcriptomics identified inflammatory genes and transcription factor mRNAs such as Yap1 and Trp53 as key targets of Ro5‐3335 in CS‐AKI. In conclusion, RUNX1 contributes to AKI by driving the expression of genes involved in inflammation and represents a novel therapeutic target in AKI. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Acute Kidney InjuryCore Binding Factor Alpha 2 SubunitLipopolysaccharidesAnimalsHumansDisease Models, AnimalMice, Inbred C57BLFolic AcidCytokine TWEAKInterleukin-6MaleMiceKidney TubulesSignal Transduction

Author keywords

LPSRUNX1Ro5‐3335TWEAKacute kidney injuryinflammation

Substances

Core Binding Factor Alpha 2 SubunitRUNX1 protein, humanRunx1 protein, mouseLipopolysaccharidesFolic AcidCytokine TWEAKInterleukin-6Tnfsf12 protein, mouseinterleukin-6, mouse

Authors and institutions

  • Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, Madrid, Spain.
  • RICORS2040, Madrid, Spain.
  • Unidad de Reumatologia, Hospital Clinico San Carlos, Madrid, Spain.
  • Unidad de Bioinformatica, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Department of Pharmacology, Universidad Autonoma de Madrid, Madrid, Spain.
  • Department of Medicine, Universidad Autonoma de Madrid, Madrid, Spain.

ORCID profiles: Julio M Martinez-Moreno, Ana B Sanz

Funding

  • COST (European Cooperation in Science and Technology)
  • Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040
  • European Cooperation in Science and Technology
  • Instituto de Salud Carlos III

Cite

APA

Fontecha-Barriuso, M., Villar-Gomez, N., Guerrero-Mauvecin, J., Martinez-Moreno, J. M., Carrasco, S., Martin-Sanchez, D., Rodríguez-Laguna, M., Gómez, M. J., Sanchez-Niño, M. D., Ruiz-Ortega, M., Ortiz, A., & Sanz, A. B. (2024). Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury. The Journal of Pathology, 264(4), 396-410. https://doi.org/10.1002/path.6355

Vancouver

Fontecha-Barriuso M, Villar-Gomez N, Guerrero-Mauvecin J, Martinez-Moreno JM, Carrasco S, Martin-Sanchez D, et al. Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury. The Journal of Pathology. 2024;264(4):396-410. doi:10.1002/path.6355

BibTeX
@article{FontechaBarriuso2024,
  author = {Fontecha-Barriuso, Miguel and Villar-Gomez, Natalia and Guerrero-Mauvecin, Juan and Martinez-Moreno, Julio M and Carrasco, Susana and Martin-Sanchez, Diego and Rodríguez-Laguna, María and Gómez, Manuel J and Sanchez-Niño, María D and Ruiz-Ortega, Marta and Ortiz, Alberto and Sanz, Ana B},
  title = {Runt‐related transcription factor 1 ( RUNX1 ) is a mediator of acute kidney injury},
  journal = {The Journal of Pathology},
  year = {2024},
  volume = {264},
  number = {4},
  pages = {396--410},
  doi = {10.1002/path.6355}
}
Start for free →